Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
The hospital said the new centre will improve access to specialised interventions such as Deep Brain Stimulation
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
He brings extensive cross-functional expertise built through leadership roles
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
Subscribe To Our Newsletter & Stay Updated
